Skip navigation
Watchlist Sponsored By :


Current DateTime: 07:09:11 15 Nov 2009
LinksList Documentid: 24355697

FEATURED QUIZZES


Current DateTime: 07:09:11 15 Nov 2009
LinksList Documentid: 33793611
  • The Billionaire BFF's

      Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?

  • The Many Myths of Coca-Cola

      Can you tell which statements are true, and which ones are just rumors?

  • Think You Understand Markets?

      We've selected some questions from the Financial Industry Regulatory Authority's test of investor knowledge. See how you do ...


Current DateTime: 07:09:12 15 Nov 2009
LinksList Documentid: 24890560
  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

  • Investor's Guide to Real Estate

      Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.

  • Alternative Investing

      Stocks and bonds? Sure. But it's a big world out there for investors.

powered by digg
Elan Shares Plunge 50%, Biogen Tumbles in Germany
By: Reuters | 01 Aug 2008 | 08:35 AM ET
Text Size

Shares in Irish drugmaker Elan dived more than 50 percent to their lowest level since 2005 on Friday as a second product setback in a week shattered confidence in its line-up of biotech medicines.

Elan and its U.S. partner Biogen Idec [BIIB  Loading...      ()   ] revealed late on Thursday two new brain disease cases in patients taking their Tysabri multiple sclerosis drug, which has already been pulled from the market once on safety fears.

Shares of Biogen sank 23 percent in German trading.

"This is a huge blow to Tysabri," Jack Gorman, an analyst at Davy, which acts as stockbroker to Elan, said in a research note.

"Although the risk management programme seems to have picked them up quickly, which is good, the impact on neurologist take-up puts our forecasts at serious risk."

Second-quarter sales of the product totalled $200 million.

The latest slide means shares in Dublin-based Elan have lost three quarters of their value this week. The stock slumped 30 percent on Wednesday after disappointing data on an experimental Alzheimer's drug Elan is developing with Wyeth. (See accompanying video for more on Elan and Biogen's stocks...)

The shares were off 54 percent at 6.20 euros in morning trading, after a low of 4 euros.

The news delivered a fresh blow to the Irish stock market which is the world's second worst performing behind Vietnam over the last 12 months. Elan's slide dragged the Irish Stock Exchange Index 7 percent lower on Friday.

Elan had been one of the few gainers this year on a market that has slumped 60 percent since early 2007 and is heavily weighted with banks and construction companies hit by the bursting of Ireland's property bubble.

Elan, whose recovery from a brush with bankruptcy in 2002 has been linked closely to Tysabri, will hold a conference call with Biogen at 1:30 pm London time.

No Plany to Pull Drug

Tysabri was withdrawn in 2005 after three patients developed the potentially deadly brain infection progressive multifocal leukoencephalopathy (PML). The drug returned to the market in
2006 with warnings and tougher prescription guidelines.

A company spokeswoman said the withdrawal of Tysabri was not under consideration, adding that new cases of PML had always been expected.

"The benefit-risk profile of Tysabri remains favorable," she said.

Tysabri and bapineuzumab, the experimental Alzheimer's drug under development with Wyeth, accounted for most of the value in analysts' financial models for Elan -- at least up until this
week.

Gorman said his sum-of-the-parts $27-32 valuation for the group's U.S. shares attributed $16.50 a share to Alzheimer's, $8.50 to Tysabri and the balance to other operations, including
the drug technology unit that Elan is looking to sell or float.

That calculation is now under review after the stock hit $11 in after-hours trade in New York on Thursday.

UBS and Credit Suisse analysts cut their price targets for the Dublin-listed shares to 14 from 24 euros and to 16 from 20 euros respectively.

Elan and Biogen sought to put the latest brain disease cases in perspective, pointing out that more than 31,800 patients were being treated with Tysabri as of the end of June.

The partners hope to get 100,000 patients on therapy by the end of 2010.

Goodbody analyst Ian Hunter agreed the number of PML cases was extremely low but said the fact that both cases occurred in patients who had been on the drug for over a year was a concern.

Copyright 2009 Reuters. Click for restrictions.
Tools:
Print EmailAdd This share icon
  • digg share

CNBC HIGHLIGHTS

  • Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
  • Brian L. Roberts
  • For the chief of cable company Comcast, growth has been about making deals – generally very large deals.
  • Some companies may start using insurance to shift carbon risk from their balance sheets to maybe... yours?
  • The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
  • Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.
  • A wealthy, distracted Texas driver crashed his million-dollar Bugatti Veyron sports car into a salt marsh, say police.
ADD COMMENTS
Remaining characters


Current DateTime: 01:02:03 15 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 01:02:04 15 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 01:02:04 15 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:02:04 15 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters